Elucida Oncology: Elucida unveils positive safety data from Phase I trial of ELU001
ELU001 has around 20 molecules of the topoisomerase-1 inhibitor exatecan-linked through a proteolytic cleavable linker. The post Elucida unveils positive safety data from Phase I trial of ELU001 appeared first on Clinical Trials Arena.
Read full article »
Elucida Oncology is a New Jersey-based clinical-stage biotechnology company that researches and develops novel therapeutics for the treatment of cancer.
Read more